Back to results
US 2024/0197840 A1Published application
Tissue Modifier And Uses Therefor
AssigneeFibrosoft Pte Ltd
InventorDavid Chin
Life of this patent
Estimating the term…
Abstract
Disclosed are compositions, methods, uses, kits and articles of manufacture, which are based on the use of a hyaluronidase and a collagen-reducing agent, for reducing or inhibiting the development of fibrosis in a tissue, or for treating collagen-mediated disorders. In specific embodiments, the collagen-mediated disorders are fibroproliferative disorders involving alterations of collagen, including fibromatoses such as Dupuytren's disease. Peyronie's disease and Ledderhose's disease.
Claims20
1-76. (canceled)
A pharmaceutical composition comprising:
- a plasminogen activator in an amount of about 1 mg to about 50 mg per single unit dose, wherein the plasminogen activator is a tissue plasminogen activator (tPA) or a urokinase type plasminogen activator (uPA);
- and
- a hyaluronidase in amount of from about 0.4 mg to about 2 mg per single unit dose, wherein the hyaluronidase is selected from Amphadase, Hyalase, Hydase, Hylase, rHuPH20/Hylenex, Vitrase, and Wydase.
Dependencies are inferred from the claim text.